Related Experiment Video
Updated: Jun 28, 2025
12:08
Diagonal Method to Measure Synergy Among Any Number of Drugs
Published on: June 21, 2018
18.5K
β-blockers are not all the same: pharmacologic similarities and differences, potential combinations and clinical
Stefano Taddei1, Nqoba Tsabedze2, Ru-San Tan3,4
1Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Current Medical Research and Opinion
|April 10, 2024
Summary
Beta-blockers are diverse drugs used for hypertension. Cardioselective beta-blockers reduce side effects, and combining them with other agents enhances blood pressure control.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Hypertension Management
Background:
- Beta-blockers represent a diverse drug class with varying selectivity for adrenergic receptors (β1, β2, α) and additional properties like partial agonism, vasodilatory effects, and lipophilicity.
- Cardioselectivity (β1-adrenoceptor selectivity) is crucial for minimizing adverse effects associated with β2-adrenoceptor blockade, such as peripheral vasoconstriction and respiratory issues.
- Updated European Society of Hypertension guidelines recommend beta-blockers as a foundational therapy for hypertension.
Purpose of the Study:
- To highlight the heterogeneity of beta-blocker agents and their distinguishing characteristics.
- To emphasize the clinical significance of cardioselectivity in mitigating adverse events.
- To discuss the role of beta-blockers in contemporary antihypertensive strategies, particularly in combination therapy.
Main Methods:
- Review of pharmacological properties of beta-blockers, including receptor selectivity, intrinsic activity, vasodilatory capacity, and lipophilicity.
- Analysis of clinical implications of cardioselectivity versus non-cardioselectivity.
- Examination of current hypertension treatment guidelines and the positioning of beta-blockers within them.
Main Results:
- Beta-blockers differ significantly in their selectivity profiles and additional pharmacological actions.
- Cardioselective agents offer a reduced risk of side effects like cold extremities, erectile dysfunction, and exacerbation of obstructive lung diseases.
- Beta-blockers are integral to antihypertensive regimens, with combination therapy potentially optimizing efficacy and outcomes.
Conclusions:
- The heterogeneity of beta-blockers necessitates careful agent selection based on patient-specific factors and desired therapeutic outcomes.
- Cardioselective beta-blockers are preferred for reducing the incidence of non-cardiac adverse effects.
- Strategic combination of beta-blockers with complementary antihypertensive agents represents a rational approach to enhance blood pressure control and clinical benefits.
Related Concept Videos
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
593
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
593
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
794
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
794
01:28Antihypertensive Drugs: Types of β-Blockers
671
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
671
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
442
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
442
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
741
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
741